Table 4. Multivariate Cox proportional hazards analysis of survival factors in the PROS1 mutation group.
| Characteristic | HR | 95% CI | p-value |
|---|---|---|---|
| Age_at_diagnosis | 1 | 0.99, 1.01 | >0.9 |
| Gender | |||
| Female | — | — | |
| Male | 1.01 | 0.88, 1.18 | 0.8 |
| Race_new | |||
| White | — | — | |
| Black or African American | 1.2 | 0.94, 1.53 | 0.2 |
| Other | 0.85 | 0.67, 1.07 | 0.2 |
| Stage | |||
| Stage I | — | — | |
| Stage II | 1.89 | 1.59, 2.26 | <0.001 |
| Stage III | 2.12 | 1.76, 2.56 | <0.001 |
| Stage IV | 1.62 | 1.18, 2.22 | 0.003 |
| Tissue_or_organ_of_origin | |||
| Lower lobe, lung | — | — | |
| Lung, NOS | 0.72 | 0.49, 1.06 | 0.1 |
| Middle lobe, lung | 1.34 | 0.94, 1.90 | 0.11 |
| Upper lobe, lung | 1.18 | 1.01, 1.39 | 0.034 |
| Treatment_type2 | |||
| Chemotherapy | — | — | |
| Ancillary Treatment | 1.55 | 0.49, 4.91 | 0.5 |
| Immunotherapy (Including Vaccines) | 2.41 | 0.76, 7.59 | 0.13 |
| Pleurodesis, NOS | — | — | |
| Radiation | 1.04 | 0.88, 1.23 | 0.6 |
| Targeted Therapy | 0.98 | 0.81, 1.18 | 0.8 |
| Laterality | |||
| Left | — | — | |
| Right | 1.2 | 1.04, 1.39 | 0.014 |
| Counts | 0.99 | 0.94, 1.05 | 0.7 |
Survival analysis in PROS1 mutation group (Multivariable).